HSPB8

Across TCGA pan-cancer cohorts, HSPB8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSPB8 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher HSPB8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSPB8 expression acts as an unfavorable survival marker.

SKCM, ESCA, and PRAD are the cancer types where HSPB8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.175	0.760	<.001	21	view →
ESCA	OS	Median	All	0.176	0.700	.006	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSPB8–SKCM (DFS)

Open the SKCM breakdown →